Chengxun Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Low Density Lipoprotein

Radical Prostatectomy

Gene Expression

Top Venues

Molecular cancer therapeutics

Small (Weinheim an der Bergstrasse, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Chengxun Li, Wenzhuo Zhao, Zuojian Hu, Hongxiu Yu
Cholesterol-Modified DNA Nanostructures Serve as Effective Non-Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury. Small (Weinheim an der Bergstrasse, Germany) 20 (30) (2024)
Chengxun Li, Wenzhuo Zhao, Zuojian Hu, Hongxiu Yu
Cholesterol-Modified DNA Nanostructures Serve as Effective Non-Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury. Small (Weinheim an der Bergstrasse, Germany) 20 (30) (2024)
Chengxun Li, Wenzhuo Zhao, Zuojian Hu, Hongxiu Yu
Cholesterol-Modified DNA Nanostructures Serve as Effective Non-Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury. Small (Weinheim an der Bergstrasse, Germany) (2024)
Chengxun Li, Jiale Zhang, Qiming Wu, Anuj Kumar, Guihong Pan, David J Kelvin
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. Molecular cancer therapeutics 22 (3) (2023)
Chengxun Li, Jiale Zhang, Qiming Wu, Anuj Kumar, Guihong Pan, David J Kelvin
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. Molecular cancer therapeutics 22 (3) (2023)
Chengxun Li, Jiale Zhang, Qiming Wu, Anuj Kumar, Guihong Pan, David J Kelvin
Nifuroxazide activates the parthanatos to overcome TMPRSS2：ERG fusion-positive prostate cancer. Molecular cancer therapeutics (2023)
Chengxun Li, Jiale Zhang, Qiming Wu, Anuj Kumar, Guihong Pan, David J Kelvin
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. Molecular cancer therapeutics 22 (3) (2023)
Chengxun Li, Jiale Zhang, Qiming Wu, Anuj Kumar, Guihong Pan, David J Kelvin
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. Molecular cancer therapeutics 22 (3) (2023)